By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biotech startup KellBenx announced on Monday a licensing agreement with Cedars-Sinai Medical Center in Los Angeles for three interleukin biomarkers for the development of a blood-based test to predict premature births.

According to the KellBenx, the agreement is the first step to the possible development of a minimally invasive test that can predict preterm delivery early in pregnancy or even before a woman becomes pregnant.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.